Skip to Main Content

Author Details

Li Liu
Central South University
2006
36
12
PMIDPaper TitleJournal TitlePublished Year
36858002Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer.Lung Cancer2023
37596822Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features.Thorac Cancer2023
37350968Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer.Front Immunol2023
37118803Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.BMC Med2023
34985386LncRNA HOXD-AS1 affects proliferation and apoptosis of cervical cancer cells by promoting FRRS1 expression via transcription factor ELF1.Cell Cycle2022
38089452Application of informatics in cancer research and clinical practice: Opportunities and challenges.Cancer Innov2022
35410334Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.BMC Med2022
35529791The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.Transl Lung Cancer Res2022
35814395Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.Front Oncol2022
36439441PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study.Front Oncol2022
35940055First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.Eur J Cancer2022
36064386Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.BMC Cancer2022
36199793Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.J Oncol2022
33975825Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.BMJ2021
33643442The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.Ther Adv Med Oncol2021
34867332Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study.Front Pharmacol2021
34660287A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.Front Oncol2021
34713636Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.Cancer Commun (Lond)2021
34249687Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.Front Oncol2021
32191330Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.JAMA Netw Open2020
31982639Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.Lung Cancer2020
33171317Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.Eur J Cancer2020
32112982Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.J Thorac Oncol2020
30762435The Role of Significantly Deregulated MicroRNAs in Recurrent Cervical Cancer Based on Bioinformatic Analysis of the Cancer Genome Atlas Data.J Comput Biol2019
31403034Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.Front Oncol2019
31632500Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway.J Cancer2019
31333800Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway.J Cancer2019
30896637The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer.Medicine (Baltimore)2019
30410351Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.Onco Targets Ther2018
30233895Lung adenocarcinoma patient progression with gastrointestinal metastasis response to subsequent tyrosine kinase inhibitors (TKIs) from re-biopsy of new occurring driver gene mutation.J Thorac Dis2018
30320371HLTF suppresses the migration and invasion of colorectal cancer cells via TGF⿿β/SMAD signaling in vitro.Int J Oncol2018
29383158The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer.Oncotarget2017
28005837Multiple Roles of WNT5A in Breast Cancer.Med Sci Monit2016
24071689[Expression of galectin-7 and S100A9 and development of cervical squamous carcinoma].Zhong Nan Da Xue Xue Bao Yi Xue Ban2013
21566277Experimental study of HSP27 differential expression in left sided colon cancer and right sided colon cancer.Zhong Nan Da Xue Xue Bao Yi Xue Ban2011
16562672[Lymphangiogenes and location of tumor lymphatic vessels induced by VEGF-C in primary breast carcer].Zhong Nan Da Xue Xue Bao Yi Xue Ban2006
  • 1 - 36 of 36

Recommended Authors

Xue Wu
Nanjing Geneseeq Technology Inc.
Career Start Year 2016
Number of shared co-authors 0
Yi Zhao
the First Affiliated Hospital of Guangzhou Medical University
Career Start Year 2013
Number of shared co-authors 0
Zhixin Qiu
UPMC Hillman Cancer Center
Career Start Year 2012
Number of shared co-authors 0
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 0
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 2012
Number of shared co-authors 0
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Fei Li
Shanghai Pulmonary Hospital, Tongji University School of Medicine
Career Start Year 2010
Number of shared co-authors 0
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Shingo Sakashita
National Cancer Center Exploratory Oncology Research & Clinical Trial Center
Career Start Year 2008
Number of shared co-authors 0
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Yin Guan
DHC Technologies Co. Ltd.
Career Start Year 2008
Number of shared co-authors 28
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 0
Jun Huang
the First Affiliated Hospital of Guangzhou Medical University
Career Start Year 2006
Number of shared co-authors 0
Hye Ryun Kim
Yonsei Cancer Center, Yonsei University College of Medicine
Career Start Year 2005
Number of shared co-authors 0
Yue Yang
Peking University Cancer Hospital
Career Start Year 2005
Number of shared co-authors 0
Fan Zhang
Huaihe Hospital of Henan University
Career Start Year 2004
Number of shared co-authors 0
Hae-Yun Jung
College of Life Science, CHA University
Career Start Year 2003
Number of shared co-authors 0
Jeeyun Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2003
Number of shared co-authors 0
Yongmei Song
Shandong University of Traditional Chinese Medicine
Career Start Year 2003
Number of shared co-authors 0
Wenhua Liang
The First People's Hospital of Zhaoqing
Career Start Year 2003
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Xin Yang
Peking University Cancer Hospital & Institute
Career Start Year 2002
Number of shared co-authors 0
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 0
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 0
Ni Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 0
Dong Lin
Fujian Medical University Cancer Hospital and Fujian Cancer Hospital
Career Start Year 1996
Number of shared co-authors 0
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 0
Enhua Wang
The First Hospital and College of Basic Medical Sciences, China Medical University
Career Start Year 1990
Number of shared co-authors 0
Pasi A J??nne
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 0

Collaborators

Jaehyeong Cho
Yonsei University College of Medicine
Co-authored papers 1
Nigam H Shah
Stanford University
Co-authored papers 1
Ying Zhang
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Co-authored papers 1
Lisa M Schilling
University of Colorado Anschutz Medical Campus
Co-authored papers 1
Elena Roel
Universitat Autonoma de Barcelona
Co-authored papers 1
Michael Matheny
American College of Medical Informatics, Department of Veteran Affairs, Harvard University T H Chan School of Public Health, Massachusetts Institute of Technology, The American Society for Clinical Investigation, University of Kentucky, Vanderbilt University Medical Center, Vanderbilt University Medical School
Co-authored papers 1
Christian Reich
OHDSI Center at The Roux Institute, Northeastern University
Co-authored papers 1
Asieh Golozar
Northeastern University
Co-authored papers 1
Dalia Dawoud
Stanford University
Co-authored papers 1
Jose D Posada
Universidad del Norte
Co-authored papers 1
Fred Nyberg
University of Gothenburg
Co-authored papers 1
Lin Zhang
Chinese Academy of Medical Sciences and Peking Union Medical College
Co-authored papers 1
Patrick B Ryan
Columbia University Irving Medical Center
Co-authored papers 1
Osaid Alser
Massachusetts General Hospital, Harvard Medical School
Co-authored papers 1
Martina Recalde
Universitat Autonoma de Barcelona
Co-authored papers 1
Paras P Mehta
College of Medicine, University of Arizona
Co-authored papers 1
Karishma Shah
University of Oxford
Co-authored papers 1
Heba Alghoul
Islamic University of Gaza
Co-authored papers 1
Carlos Areia
University of Oxford
Co-authored papers 1
Jitendra Jonnagaddala
NMC Royal Hospital
Co-authored papers 1
Kristin Kostka
OHDSI Center at The Roux Institute, Northeastern University
Co-authored papers 1
Paula Casajust
Co-authored papers 1
Waheed-Ul-Rahman Ahmed
University of Oxford
Co-authored papers 1
Hong-Bo Zhu
The First Affiliated Hospital, Hengyang Medical School, University of South China
Co-authored papers 1
Jennifer C E Lane
Queen Mary University of London
Co-authored papers 1
Talita Duarte-Salles
Erasmus University Medical Center
Co-authored papers 1
Kristine E Lynch
University of Utah Health
Co-authored papers 1
Daniel Prieto-Alhambra
University of Oxford
Co-authored papers 1
Edward Burn
University of Oxford
Co-authored papers 1
Anthony G Sena
Erasmus University Medical Center
Co-authored papers 1
Release 1.2